The Risk of Dermatological Toxicities of Combined BRAF and MEK Inhibition Versus BRAF Inhibition Alone in Melanoma Patients: A Systematic Review and Meta-Analysis
December 2018
in “
Cutaneous and Ocular Toxicology
”
Studysummary This meta-analysis found that combined BRAF and MEK inhibitor treatment in melanoma patients is linked to increased all-grade rash but reduced risks of several other dermatological toxicities compared to BRAF inhibition alone.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer